MRK Stock Recent News

MRK LATEST HEADLINES

MRK Stock News Image - Investors Business Daily

Merck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the first week of 2024.

Investors Business Daily 2024 Jan 08
MRK Stock News Image - Seeking Alpha

Merck is a pharmaceutical giant whose medications and vaccines play key roles in the fight against viruses, cancer, and cardiovascular diseases. On October 26, 2023, Merck published results for the 3rd quarter of 2023, which left mixed feelings. The exclusivity of most of the company's medications and vaccines is set to expire within the next five years.

Seeking Alpha 2024 Jan 08
MRK Stock News Image - WSJ

Merck has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million.

WSJ 2024 Jan 08
MRK Stock News Image - Reuters

Merck & Co said on Monday it would buy cancer drug developer Harpoon Therapeutics for about $680 million, reinforcing its oncology portfolio with immunotherapies.

Reuters 2024 Jan 08
MRK Stock News Image - Proactive Investors

Merck & Co Inc (NYSE:MRK) is close to acquiring Harpoon Therapeutics Inc, a cancer drug developer, for about $700 million to bolster its oncology portfolio. The proposed deal, which could value Harpoon at $23 per share, aligns with Merck's strategy to seek new growth opportunities as its top-selling cancer drug Keytruda faces future pricing pressures.

Proactive Investors 2024 Jan 08
MRK Stock News Image - Market Watch

Merck MRK, +0.18% is in talks to buy cancer drugmaker Harpoon Therapeutics HARP, -1.49% for about $700 million, or $23 per share, Bloomberg News reported, citing people familiar with the matter. Merck didn't comment to Bloomberg, the report said, while Harpoon didn't respond.

Market Watch 2024 Jan 08
MRK Stock News Image - Reuters

Merck & Co is in advanced talks to buy cancer drugmaker Harpoon Therapeutics Inc for around $700 million, Bloomberg News reported on Sunday, citing people familiar with the matter.

Reuters 2024 Jan 08
MRK Stock News Image - Reuters

Merck & Co's Chief Executive Officer Robert Davis said on Thursday the company is seeking GLP-1 treatments with benefits beyond weight loss.

Reuters 2024 Jan 04
MRK Stock News Image - Zacks Investment Research

In the latest trading session, Merck (MRK) closed at $114.77, marking a +1.35% move from the previous day.

Zacks Investment Research 2024 Jan 03
MRK Stock News Image - Seeking Alpha

The Weekly MDA Breakouts completed the best year since this model was released on Seeking Alpha in 2017. In 2023, 125 picks gained over 5% and 65 picks gained over 10% in their measured week, with simulated annual returns of 253.46%. The MDA Breakout model has historically had a compound average growth rate of 45.7% and cumulative returns of +1,348.2% since 2017.

Seeking Alpha 2023 Dec 31
10 of 50